Upper aerodigestive cancer is an aggressive malignancy with relatively stagnant long-term survival rates over 20 yr. Recent studies have demonstrated that exploitation of PPARg pathways may be a novel therapy for cancer and its prevention. We tested whether PPARg is expressed and inducible in aerodigestive carcinoma cells and whether it is present in human upper aerodigestive tumors. Human oral cancer CA-9-22 and NA cell lines were treated with the PPAR activators eicosatetraynoic acid (ETYA), 15-deoxy-d-12,14-prostaglandin J2 (PG-J2), and the thiazolidinedione, ciglitazone, and evaluated for their ability to functionally activate PPARg luciferase reporter gene constructs. Cellular proliferation and clonogenic potential after PPARg ligand treatment were also evaluated. Aerodigestive cancer specimens and normal tissues were evaluated for PPARg expression on gene expression profiling and immunoblotting. Functional activation of PPARg reporter gene constructs and increases in PPARg protein were confirmed in the nuclear compartment after PPARg ligand treatment. Significant decreases in cell proliferation and clonogenic potential resulted from treatment. Lipid accumulation was induced by PPARg activator treatment. 75% of tumor specimens and 100% of normal control tissues expressed PPARg RNA, and PPARg protein was confirmed in 66% of tumor specimens analyzed by immunoblotting. We conclude PPARg can be functionally activated in upper aerodigestive cancer and that its activation downregulates several features of the neoplastic phenotype. PPARg expression in human upper aerodigestive tract tumors and normal cells potentially legitimizes it as a novel intervention target in this disease.
INTRODUCTION
In spite of advances in molecular biology of squamous cell carcinoma of the head and neck (SCCHN) and multi-modality treatments, the 20-50% survival of stage III and IV disease has not changed appreciably over 20 yr [1] . As a consideration to improve efficacy of conventional treatment or for chemoprevention, nuclear receptor targeting with retinoids continues to be an important focus, however early successes were limited by retinoid toxicity and reversal of differentiation changes upon cessation of treatment [2, 3] . Peroxisome proliferator-activated receptors (PPARs) are transcription factors belonging to the steroid/thyroid/retinoic acid nuclear receptor superfamily and are promising new targets. One isoform, PPARg, heterodimerizes with RXRa to form a functional transcription factor which promotes adipocyte differentiation [4] .
Natural and synthetic fatty acids, including the arachidonic acid analog, eicosatetraynoic acid (ETYA), are PPARg activators [5] . ETYA and related agents dramatically downregulate cell growth and promote features consistent with differentiation in a variety of cell lines [6] [7] [8] [9] [10] [11] . Previous experiments with ETYA demonstrated that structurally distinct lipoxygenase inhibitors have a variety of antineoplastic features not entirely explained by the inhibition of lipoxygenase alone [12] [13] [14] [15] . Several anticancer effects of these drugs may be attributable to PPARg activation [16, 17] .
PPARg was originally identified in adipocytes [18, 19] and strongly directs adipocyte differentiation, even when ectopically expressed in fibroblasts [19, 20] . Feasibility of targeting cancer with PPARg treatment began with observations of anti-cancer effects after use of these agents in liposarcoma cell lines [21, 22] which led to liposarcoma patient studies [23, 24] . Clinically, pioglitazone and rosiglitazone, agents of the thiazolinedione class of drugs which specifically target PPARg, are FDA approved treatments for Type II diabetes, and exhibit interesting anticancer properties. PPARg-based therapy in breast cancer models demonstrated inhibition of cell cycle progression, induction of apoptosis, extensive lipid accumulation, decreased growth rate and clonogenicity, and promotion of cancer prevention in animal models [25] [26] [27] [28] [29] [30] . Activation of PPARg in lung cancer cell lines has induced differentiation and apoptosis [20, [31] [32] [33] . Additional recent studies provide further evidence demonstrating these agents may be useful in colon, neural, ovarian, melanoma, and lung cancer [34] [35] [36] [37] [38] [39] [40] [41] [42] ; however, mechanisms of downstream action may vary between tissue types. In colon cancer, a principal finding of ciglitazone treatment was alterations in chaperones associated with protein folding [35] . In ovarian cancers, ciglitazone resulted in alterations in glucose transporters. In one recent breast cancer study in MCF-7 cells, ciglitazone and rosiglitazone affected cyclin D1 and augmented doxorubicin activity through cyclin D1 interactions [38] . Another breast study demonstrated modulation of leptin and VEGF as an exploitable treatment with PPAR activators [41] . In non-small cell lung cancer, radiosensitizing effects were observed as well [39] . The potential role for PPARg to modulate the early events in carcinogenesis has even spawned considerable interest in this transcription factor as a target for chemoprevention [43] . The fact that these agents affect a transcription factor system and perhaps hundreds of downstream genes, including pathways and cellular processes other than differentiation, may allow for many opportunities for biomarker discovery.
Cancer largely represents a lack of differentiation and driving premalignant or cancerous cells into a terminally differentiated state is an attractive therapeutic strategy. Differentiation therapy has been successfully used in acute promyelocytic leukemia, hairy cell leukemia, and childhood neuroblastoma [44, 45] . Retinoid therapy has shown mixed results in solid tumor treatment or chemoprevention [2, 46, 47] . Presently, we examined oral cancer cell lines and tumor specimens for the expression of PPARg. We treated cell lines with three chemically distinct ligands of PPARg (ETYA, PG-J2, and the prototypic thiazolidinedione, ciglitazone) which caused dose-dependent inhibition of proliferation and cytoplasmic lipid vacuole accumulation and morphologic changes consistent with cellular differentiation with an adipogenic phenotype shift. Electromobility supershift analysis demonstrated specific DR-1 and cyp4A1 consensus sequence binding activity in nuclear extracts which was upregulated with PPARg ligand treatment. PPARg and RXRa were identified as the predominant binding partners in control and ligand-stimulated nuclear extracts. Functional activation of the PPAR response element (PPRE) demonstrated increased PPRE activation with each ligand and also in the fat specific protein aP2 (fatty acid binding protein, FABP4). Microarray interrogation demonstrated PPARg expression was decreased in human head and neck squamous cancer specimens compared to normal oral mucosa. We conclude PPARg ligands represent a class of drugs which have value in the treatment of SCCHN and its precursor lesions.
MATERIALS AND METHODS

Cell Culture
Mycoplasma free CA-9-22 and NA EGFR positive oral cavity cell lines [48] were cultured at 378C, 5% CO 2 as adherent monolayer cultures in RPMI 1640 media supplemented with 2 mM Glutamine, 10% heat-inactivated FBS (Gibco/BRL), 50 u/mL Penicillin, and 50 mg/mL streptomycin. Log-phase cells were routinely subcultured weekly after trypsinization.
Preparation of Nuclear Extracts
Extracts from log-phase squamous cancer cell lines were prepared according to the methods of Dignan, utilizing some of the modifications of Lee as previously published [12] . Protein concentrations of all samples were determined by the Bicinchoninic Acid (BCA) modification of the Biuret Reaction (Pierce Protein Assay kit, Pierce, Rockford, IL) with bovine serum albumin as standards. Plates were read at 560 nm on a Tecan spectrophotometer (Tecan, Durham, NC). All samples were assayed in triplicate and standard curves generated by least squares analysis, to a zero order function utilizing Spectra Software. Correlation coefficients for the functions were greater than 0.97 in all experiments. All protein concentrations were calculated from the central portion of the curve. Standard curves were generated by least squares analysis to a zero order function utilizing Spectra Software. Correlation coefficients (r 2 ) for the functions were greater than 0.95 in all experiments.
Aerodigestive Cancer Cell Line Western Blotting
Cells were grown in 75 cm 2 or 150 cm 2 flasks to 60-80% confluence and treated with respective agents in serum free media. Nuclear extracts were prepared as described under "Preparation of Nuclear Extracts." Twenty micrograms of nuclear extract protein were added to equal volume of 2Â sample buffer (1.0 mL glycerol, 0.5 mL beta-mercaptoethanol, 3 mL 10% SDS, 1.25 mL 1.0 M Tris-HCl, pH 6.7, 1.5 mg bromophenol blue) and loaded into a 1.5 mm 10% polyacrylamide gel and run at 20 mA for 2 h at 48C. Gels were removed and incubated in transfer solution (25 mM Tris base, 192 mM glycine, 20% methanol) for 5 min, then transferred to nitrocellulose membrane using a semi-dry transfer unit (Hoeffer). Blots were blocked in 3% milk blocking solution (1Â TBS, 3% Milk, 0.05% Tween 20) for 1 h at 48C. Following TBS rinse (10 mM Tris-HCl, pH 8.0; 150 mM NaCl), blots were incubated in primary antibody at 1:1000 (Santa Cruz Biotech Inc. sc-7273 mouse monoclonal anti-human PPARg, Santa Cruz, CA) in blocking solution overnight. Blots were briefly rinsed, then incubated secondary antibody at 1:2000 (Santa Cruz Biotech Inc., goat anti-mouse HRP). Following rinse, the blots were developed using chemiluminescence technique with Santa Cruz reagents per manufacturer protocol, and exposed to film.
Electromobility Shift Assays
Probe preparation 
EMSA Binding Reactions and Shift Assays
EMSA binding reactions consisted of 5 mg of nuclear extract protein prepared as under "Preparation of Nuclear Extracts" above and identically as previously published. The gels were dried and imaged by phosphor imaging with a Packard Cyclone Phosphorimager utilizing MP imaging screens and analyzed by Optiquant software (Packard Technologies, Downers Grove, IL). All EMSA reactions were carried out on at least three separate nuclear extract preparations. For supershift experiments, 1 mg of antibody for RXR alpha (sc553Â) or PPARg (sc7273) (Santa Cruz Biotech Inc.) was added 12 h prior to the binding reactions with the labeled probes, and the EMSAs were carried out at 48C. Densitometry analysis was performed using Optiquant software.
Transient Transfections/Luciferase Assays
All cell lines were transiently transfected with a PPRE reporter plasmid (TK-PPREx3-LUC [PPRE Â 3(5 0 -TCGA-CAGGGGACCAGGACAAAGGTCACGTTCGGGAGTC-GAC), three copies] kindly gifted by Dr. Ron Evans, Salk Institute, La Jolla, CA). An additional luciferase construct for the promoter of the PPARg responsive lipid metabolism gene aP2 was utilized for a second series of experiments (kindly gifted by Dr. David Bernlohr, University of Minnesota, Minneapolis, MN). The p21 promoter reporter gene plasmid (obtained from Dr. Bert Vogelstein, Addgene plasmid 16451) expresses the firefly luciferase gene under the control of a 2400 base pair segment of the p21 promoter. Briefly, cells at 60-80% confluence were exposed to 2 mg/mL TKPPREx3-LUC reporter (or aP2, or p21) construct plasmid and co-transfected with 0.4 mg/mL b-gal containing DNA reporter. Lipofectamine, at 10 mg/mL in Opti-MEM (Life Technologies, Gaithersburg, MD), was utilized for transfection. After 4 h, the media was washed free from the cells, and complete media was used for 24 h further incubation unless otherwise indicated. Following specified treatments, relative luciferase activity was assayed with a Dual-Light reporter gene assay system (Tropix, Bedford, MA) as per kit instructions. A Tropix model TR717 dual injection plate luminometer with Winglow software was utilized for the analyses. Luciferase was scaled to b-gal as an internal standard. For PPARg antagonist experiments, cells were pre-incubated for 1 h with T0070907 prior to incubation with activators. Three assays were performed in triplicate wells for a total of nine replicates per data point.
Cell Proliferation Assays
Log-phase NA and CA-9-22 cells were plated in tissue culture treated 96-well, flat-bottom plates (Falcon, Becton Dickenson Labware, Franklin, NJ) at 5000 cells/well in complete media overnight. The following morning, media was replaced with serum-free media containing PPARg ligands or the vehicle alone (ETOH or DMSO) for 72 h. Proliferation was determined by using the MTT reaction assay (Boehringer Mannheim, Indianapolis, IN) as per manufacturer instructions reading the plates on a Tecan plate spectrophotometer at 560 nm. For PPARg antagonist experiments, cells were pre-incubated for 1 h with T0070907 prior to incubation with activators. Six replicates were used for each data point and experiments repeated twice.
Clonogenic Assays
CA-9-22 and NA cells were trypsinized during log phase growth and 400 cells per well were plated in 5% media, and allowed to attach overnight. The following morning, treatment agents or appropriate vehicle controls were added. After 10 d, cell colonies representing cell numbers of 25 or more were counted after staining with crystal violet. The treatments were conducted in triplicate, experiments were repeated with similar results twice, and results were expressed as fractional number of colonies over control.
Oil Red O Studies
Cell lines were grown to 50-60% confluence in 12-well flat bottom plates; respective ligands were added in 2% media and incubated for 72 h. Cells were then harvested by trypsinization, resuspended, and fixed in CytoRich (Tripath Imaging, Inc, Burlington, NC). Oil Red O solution (0.2% in isopropyl alcohol) was then applied for 15 min; cells were then rinsed with serial concentrations of isopropyl alcohol and digital photographs were taken. Pixel counting experiments were performed using Adobe Photoshop CS5 and stained areas of fat containing vacuoles were expressed on a per cell basis.
Genomics Analysis
Patient characteristics and biopsy samples from patients and volunteer control subjects were obtained in accord with guidelines set forth by the Institutional Review Board of the Human Subjects Protection Committee at the University of Minnesota. The University of Minnesota Cancer Center Tissue Procurement Facility obtained tumor samples from surgical resection specimens from patients undergoing surgery for SCCHN using standardized procedures. All samples were immediately placed on ice and, within 30 m of devascularization, frozen in liquid nitrogen following removal of portions needed for pathological diagnosis. Histological analyses were performed to ensure that each specimen contained greater than 50% tumor tissue and less than 10% necrotic debris, and those samples not meeting these criteria were rejected. Healthy control subjects without a history of oral cancer, pre-malignant lesions or periodontal disease were recruited through the University of Minnesota School of Dentistry. Following administration of a local anesthetic, a 6 mm punch biopsy of buccal mucosa was obtained and flash frozen in liquid nitrogen until mRNA extraction (40% mucosa/60% submucosa in specimens).
Extraction of Total RNA and Probe Preparation
Fifty to 100 mg of tissue was submerged in 1 mL of Trizol reagent (Life Technologies) and immediately homogenized using a rotor-stator homogenizer (Powergen 700, Fischer Scientific) under RNAse free conditions. Total RNA was extracted from the samples using the Trizol extraction protocol following a 1-min spin at 12,000 Â g to pellet particulate matter. Total RNA was precipitated by incubating with 0.5 mL of isopropyl alcohol for 10 m followed by centrifugation at 12,000g for 10 m at 48C. The pellet was washed twice with 75% ethanol, dissolved in RNAse free water and stored at À808C until further use. Agarose gel electrophoresis was performed on each sample prior to further analysis to confirm the presence of nondegraded RNA.
Five to 10 mg of total RNA was used to prepare biotinylated cRNAs for hybridization using the standard Affymetrix protocol (Expression Analysis Technical Manual, Affymetrix, Inc., 2000). Briefly, RNA was converted to first strand cDNA using a T7-linked oligo(dT) primer (Genset, La Jolla, CA), followed by second strand synthesis (Life Technologies). The double stranded cDNA was then used as a template for labeled in vitro transcription reactions using biotinylated ribonucleotides (Enzo, Farmingdale, NY). Fifteen micrograms of each labeled cRNA was hybridized to Affymetrix U133A GeneChips (Affymetrix, Santa Clara, CA) using standard conditions in an Affymetrix fluidics station.
Analysis of Microarray Data
Pre-processing of microarray data Scanned Affymetrix array data were uploaded into the GeneData Cobi 4.0 (www.genedata.com) database maintained by the Supercomputing Institute's Computational Genomics Laboratory at the University of Minnesota. Pre-processing of the Affymetrix arrays was carried out using GeneData Refiner 3.0 (www.genedata.com) software to correct for variations in hybridization intensity due to gradient effects, dust specks, or scratches. Gene expression intensity for each array was scaled to an arbitrary value of 1500 intensity units to allow comparisons across all arrays. Expression intensity values for each gene were derived using Refiner by applying the Microarray Suite 5.0 algorithm.
Statistical analysis
Genes differentially expressed between the 41 SCCHN and 13 normal oral mucosal biopsies were identified using a Satterthwaite t-test [49] to robustly estimate significance despite unequal variance among groups.
Tumor Specimen Western Blotting
The protein layer from Trizol extracted tumors was used for the tumor immunoblotting experiments identically as per manufacturer instructions with 40 mg tumor protein loaded per lane. Specimens were obtained from central portions of the tumor and contained tumor cells and surrounding stroma and immediately frozen in dry ice. This was performed through an IRB approved tissue procurement protocol allowing for an extra biopsy from the tumor but not normal tissue or margin tissue from the tumor specimen, all at the time of surgery. Specimens were supplied without patient identifying data. The tumors for the Western blot experiment were from a different cohort of patients than the microarray experiments.
Biochemicals
Electrophoresis grade acrylamide and bis-acrylamide, PMSF, DTT, NaCl (Sigma Chemical, St. Louis, MO), Nonidet P40 (U.S. Biochemical Corp., Cleveland, OH). 
Statistical Analysis
All analyses were conducted utilizing 2-sided Student T-tests with 95% confidence intervals calculated with a statistical analysis program (Statmate, Graph Pad Software, San Diego, CA). The overall analysis of the Affymetrix chip data have been previously published [50] . For the analysis of the PPAR gene expression data, a 2-sided t-test with a correction for unequivalent variances was employed (using a Welch Correction).
RESULTS
PPARg Protein Expression and Induction in Squamous Aerodigestive Cancer
NA and CA-9-22 oral cancer cell lines were treated with PPARg activators and western blot and electromobility shift assays performed. We used three structurally diverse PPARg activators including eicosatetraynoic acid (ETYA) (a synthetic analog of arachidonic acid known to have anticancer properties), ciglitazone (a thiazolidinedione), and prostaglandin 15-deoxy-delta-12-14-PG-J2 (PG-J2). At baseline, small amounts of immunoreactive PPARg protein were present at the anticipated molecular weight in nuclear extracts from both cell lines, and this was increased after 40 h of ETYA, ciglitazone, and PG-J2 treatment ( Figure 1A ). The 40-h time point was chosen for these initial experiments to be consistent with original experiments on PPAR activation [19, 51] . These experiments were repeated three times with similar results. This data demonstrates that PPARg protein level increases in the nucleus with PPARg activator treatment in two oral cancer cell lines.
Next, to identify a potential nuclear binding partner for PPARg from the western blots, we incubated CA-9-22 cells with 10 mM ETYA for 40 h and performed EMSAs utilizing the published PPARg recognition sequence from the cyp4A1 gene promoter [21] . Nuclear extracts from untreated CA-9-22 cells contained small amounts of protein as demonstrated in lane 1 of Figure 1B . Unlabeled competition experiments with 100-fold excess of the cyp4A1 oligonucleotide are shown in lane 2 and 6. The experiments were repeated and Oct-1 was used as a housekeeping control for the experiments (not shown). These data demonstrate oral cavity cancer cells have the capacity to upregulate nuclear PPARg nuclear protein in response to three classes of PPARg activators ( Figure 1A) , and that the upregulated nuclear protein has the capacity to bind to a PPARg response element containing PPARg/RXRa dimers after ETYA treatment ( Figure 1B) .
To analyze functional activity of the PPAR gene, PPARg luciferase reporter gene experiments were conducted. Figure 2 demonstrates significant activation of the PPAR luciferase reporter after 24 h treatment in CA-9-22 and NA cells with ETYA ( Figure 2A and B Ã P < 0.0001). Next, PG-J2 treatment of both cell lines caused increases in the PPAR luciferase reporters ( Ã P < 0.0001). The maximal activation of the reporter genes occurred at a 5 mM concentration of PG-J2 in both cell lines (Figure 2C and D) . Above 5 mM, under the reporter gene conditions, apoptosis/cytotoxicity was often evident by inverted phase light microscopy. Similarly, ciglitazone treatment of both cell lines caused increases in the PPAR reporters in both cell lines ( Figure 2E and F, Ã P < 0.0001). The maximal activation of the reporter genes occurred at 5-10 mM concentration in both cell lines. These data demonstrate functional activation of PPARg in oral cancer cell lines. This fortifies the western blot and EMSA data identifying PPARg in nuclear protein extracts on western blots and EMSAs (Figure 1) . Interestingly, at 20 mM ciglitazone, cells developed an apoptotic appearance by light microscopy with floating cells present in significant numbers. Consequently, we found inconsistencies in the activations at concentrations of PG-J2 and ciglitazone above 5 mM. This was accompanied by 50% or greater decreases in the amount of b-gal activation (data not shown), probably attributable to apoptosis/cytotoxicity. 
PPARg Ligands Induce Growth Arrest and Decrease Clonogenicity of Squamous Aerodigestive Cancer Cells
To examine anti-cancer properties of PPARg activation in oral cancer, cell proliferation and colony formation were analyzed using ligand treatments with and without inhibitors. ETYA treatment of both cell lines resulted in decreased proliferation in a dosedependent fashion at concentrations of 5-40 mM ETYA ( Figure 3A and B) . The IC50 concentrations for the effects observed with ETYA are between 5 and 10 mM for CA-9-22 cells and between 10 and 20 mM for NA cells. Both cell lines also demonstrated significant dose-dependent decreases in cell proliferation with PG-J2 at 2.5 mM (the reported IC50 concentration) and above ( Figure 3C and D) [16] . Ciglitazone caused similar dose-dependent effects with an IC50 of approximately 5 mM for both cell lines. In sum, three structurally diverse PPARg activators decreased cell proliferation at similar concentrations to PPARg nuclear elevations and functional activation in Figures 1 and 2 . This demonstrates an associative link between PPARg activation and decreased proliferation in oral cancer cell lines.
Next, diminished clonogenic growth, a second anticancer property, was assessed in CA-9-22 cells after PPARg ligand treatment. ETYA at 5, 10, 20, and 40 mM was effective in significantly reducing clonogenic growth of both cell lines when assessed at 10 d (Figure 4A and B) . The IC50 for the effect was approximately 20 mM in both cell lines (IC50 for PPAR activation by ETYA is 10 mM) [5] . PG-J2 treatment significantly decreased clonogenic growth with all concentrations of the agent tested (1, 2, 5, and 10 mM). The IC50 for clonogenic growth was between 1 and 2 mM (reported IC50 for PPARg activation with PG-J2 is 2 mM). At 10 mM, PG-J2 clonogenic growth was nearly abolished with greater than 95% inhibition of colony formation. With ciglitazone, the effects were less pronounced. Ciglitazone at 4.5 mM had little effect on clonogenic growth, but concentrations of 9 and 18 mM had significant dose dependent effects, reducing growth by up to 40% after treatment. Each experiment was repeated with similar results. Taken together, these results demonstrate that three structurally diverse PPARg activators decrease two hallmark features of the neoplastic phenotype, proliferation and clonogenic growth.
To confirm the specificity of PPARg effects, antagonist studies were performed. After screening a variety of PPARg agonists, we utilized T0070907, a PPARg antagonist which covalently binds to Cys313 of PPARg, inducing conformational changes blocking the recruitment of transcriptional cofactors to PPARg/ RXR heterodimer. We pre-incubated CA-9-22 cells for 1 h and then performed PPARg luciferase reporter gene assays as well as MTT assays. Reporter gene assays revealed significant reversal of PPARg reporter gene activation when T0070907 was co-incubated with all three PPARg activators ( Figure 5A-C) . Additionally, we wanted to investigate whether these results would translate to other observations we made on MTT assays. With ETYA and ciglitazone, significant reversal of inhibition of cell proliferation occurred with 20% increases towards controls with ETYA and 15-20% with ciglitazone. With PG-J2 and T0070907, however, this effect was absent ( Figure 5D ). This likely reflects PPARg-independent anti-proliferative effects on CA-9-22 cells. We next repeated the clonogenic assay experiments with T0070907 and CA-9-22 cells. We observed the antagonist itself had no effect on clonogenic potential. However, in the case of both ETYA and ciglitazone (Supplemental Figure S1) , T0070907 antagonized the effects of both agents on clonogenic potential. Only minimal, insignificant changes in clonogenic growth were observed after 5 mM PG-J2 and T0070907 combination treatments, however, there was a significant change in clonogenic growth in the cells treated with 2.5 mM PG-J2 (35% of control colonies) versus PG-J2 and T0070907 (47% of control independent effects on cell growth were more likely to occur with PG-J2. These data strengthen support for PPARg mediated antiproliferative effects on cell growth and decreased clonogenecity, since a PPARg antagonist helps abrogate the effects observed. These data are enhanced for ETYA and ciglitazone, compared to PG-J2.
To preliminarily examine a mechanism for the observation of decreased clonogenicity and proliferation, we next tested the CA-9-22 cells for activation of the cell cycle checkpoint protein, p21. We utilized the commercially available FDA approved drug pioglitazone, a thiazolidinedione related to ciglitazone, in CA-9-22 cells. We found the p21 promoter was significantly activated 3.6-5.6 fold at 24 and 48 h after pioglitazone treatment (Table 1) . Several experiments were performed at various timepoints from 0-48 h and the observable increases occurred at 24 and 48 h (one-way ANOVA, P < 0.0001). We additionally examined Beas 2B and MSK Leuk1 cells and discovered a 10 mM ciglitazone induction of p21 promoterreporter gene activity of 25-75% over controls at 6 h. Finally, we examined our genomics data for associations between p21 and PPARg and did not find coordinate regulation between these two genes (R 2 ¼ 0.0236; P ¼ 0.4999) for the oral cancer specimens and the tumor cohort (R 2 ¼ 0.0098; P ¼ 0.5570). Together these data suggest that p21 may be a mechanistic target for thiazolidinedione action in squamous malignancy and premalignancy, but other effects must be occurring as well through other PPARg dependent genes.
Ligands of PPARg Induce Lipid Accumulation and Induce Differentiation Markers
The effect of PPARg ligands on cell morphology was assessed by light microscopy using oil-red-o staining (Supplemental Figure S2) . Cell lines treated with PPARg ligands demonstrated a morphologic change characterized by the acquisition of cytoplasmic lipid droplets. Cell pseudopod formation was observed in many cells in the plates, which is one feature of squamous epithelial differentiation [52] . At higher doses, cell rounding and decreased cell density was typically observed, consistent with cell death and inhibition of proliferation, respectively. Even in these cells, lipid droplets are observed. Decreased cell density was a consistent finding across cell lines and all PPARg ligands. Vehicle-only control cells grew to high densities. These experiments were repeated several times with similar results.
To test the hypothesis that PPARg activators may cause some level of transdifferentiation into an adipose phenotype, cells were tested for their ability to activate an adipose differentiation-specific gene aP2 (aka FABP4). In both CA-9-22 cells and NA cells, ETYA at 10 and 20 mM activated the aP2 luciferase reporter gene, with significant activation occurring with as little as 5 mM ETYA (Figure 6A and D) . Ciglitazone treatment demonstrated significant dose-dependent increases in aP2 reporter gene activation at 4.5, 9, and 18 mM concentrations in the CA-9-22 cells ( Figure 6C and F) . Similar levels of activation were observed with PG-J2 treatment ( Figure 6B and E) . Next, RT-PCR was conducted with PG-J2 and these experiments demonstrated increased FABP4 and adipsin mRNA levels after PG-J2 treatment, without increases in PPARg mRNA levels ( Figure 6G ). In aggregate, these data demonstrate increased activation and expression of adipose differentiation-specific genes after PPARg ligand treatment.
PPARg Expression in Head and Neck Tumors
In order to identify whether PPARg was an identifiable target in actual human tissues, specimens from our head and neck cancer tumor bank/data base were interrogated for their level of PPARg expression using microarray technology. Thirty four of 44 tumor specimens expressed PPARg at detectable levels (63%) whereas 100% (13/13) normal oral cavity specimens expressed PPARg (Figure 7A and B) . As a group, the normal oral cavity specimens had a higher level of expression of PPARg (342.6 AE 87.22) than the tumors (180.7 AE 45.26) (P ¼ 0.0023). More specifically, oral cavity and oropharynx cancers had lower expression of PPARg (P ¼ 0.0006) compared to normals than the overall cohort. In addition, PPAR a and d were also interrogated from the array. There were no significant differences in PPARa (P ¼ 0.5875) expression in the tumors versus the control specimens ( Figure 7B and E), however, PPARd expression was significantly diminished in the tumors (833.1 AE 38.11) compared to the controls (1163 AE 89.9) (P ¼ 0.0038) ( Figure 7C and F). There were no differences in PPAR expression across the differentiation spectrum of the malignancies (well, moderately, poor/moderate, and poorly differentiated) for PPARg (P ¼ 0.9613). Similarly, there was no statistically significant difference between patients experiencing recurrent disease for any of the PPAR proteins (P > 0.1112). Demographics for this cohort are published on page 56, Table 1 of Ginos et al. [50] .
We also compared baseline PPARg expression between oral cancer CA-9-22 cells and three keratinocyte cell line models for differences (bronchial epithelial cells: Beas 2B and transformed oral cavity epithelial cells: HOK 16B and MSK Leuk1). On qPCR we found similar expression in the oral cancer and bronchial cells, which was somewhat higher than the transformed oral cavity cell lines (HOK 16B and MSK Leuk1 cells). These data indicate that unstimulated oral cavity cell lines and cancer cells have baseline PPARg expression, and that this expression may be influenced by immortalization (data not shown).
Western analysis also revealed PPARg positive immunoreactivity in six of nine head and neck cancer specimens at the expected molecular weight of PPARg ( Figure 7G) . Three of the specimens exhibited two separate bands at molecular weights reported for PPARg1 and 2 isoforms suggesting both isotypes are present in head and neck tumors [53] . The percent of tumors which expressed PPARg upon gene bank interrogation and western analysis was similar (66% vs. 63%). Since PPARg protein is expressed in human tumor specimens, this provides further evidence that it could be putative target for intervention clinically.
DISCUSSION
There is a vital and broad need to investigate new molecular targets for therapeutic interventions for oral cancer and its prevention. A variety of PPARg Experiments examining ETYA effect on lymphoma, glioma, prostate, and head and neck cancer cell lines (under the premise that ETYA was an eicosanoid synthesis inhibitor) revealed the unexplained finding of lipid uptake in several cell lines, as well as growth inhibition [19, 20, 51] . This was felt to be a cell death phenomenon at the time. ETYA has the capacity to activate PPARa and PPARg [20] , and ETYA treatment of 3T3-L1 pre-adipocytes stimulates "terminal differentiation", presumably through its PPARg mediated properties [5] . In our experiments, ciglitazone and PG-J2 treatment support the ETYA observations. PPARg specificity for the events is strengthened by antagonist experiments with T0070907. We also observed the formation of cytoplasmic lipid droplets after PPAR ligand treatment. Further, PPARg activators promoted upregulation of FABP4 and possibly a partial adipogenic phenotype in these oral cancer cells. Together, the accumulation of cellular lipid subsequent to FABP4 activation is consistent with at least rudimentary adipocyte differentiation. In another study, PPARg ligands induced upregulation of general markers of differentiation, including gelsolin, Mad, and p21 in non-small cell lung cancer. However, no lipid specific markers or oil red O staining were observed under the experimental conditions in that study [32] .
Generally, differentiation is accompanied by decreased proliferation. The decrease in proliferation and clonogenicity we observed, in the context of lipid accumulation after FABP 4 upregulation, is consistent with a possible transdifferentiation phenomenon occurring in both squamous cancer cell lines tested. In pre-adipocyte cell culture models, the first step of adipocyte differentiation involves cell cycle and cell proliferation arrest. More importantly, from a cancer treatment or cancer prevention perspective, proliferation and clonogenicity arrest are important prerequisites for effective therapeutic compounds. Additionally, the evidence that differentiation phenomena are occurring in the cell lines adds an interesting dimension to the potential clinical translation of these findings. In particular, early phase clinical trials might include an intermediate endpoint biomarker panel related to squamous or adipocyte lineage differentiation, in addition to more typical surrogate endpoints like proliferation markers or targeted endpoints (e.g., PPARg).
We also found PPAR expression in the normal human tissue samples and human head and neck tumors. The diminished expression of PPARg nuclear receptors in tumor tissues is intriguing from an experimental therapeutic standpoint of retinoid cancer therapies. Much effort has been dedicated to analyze RARb expression in aerodigestive cancers. A principal finding is that diminished expression is associated with poorer survival in early stage lung cancer [54] . From this, a concept developed that restoring the expression of the RAR portion of nuclear receptor heterodimers would improve survival and this could be accomplished with either genetic overexpression or induction with retinoids through feed-forward growth loops which increase RARb expression [55] [56] [57] [58] . Similarly, the promotion of increased PPARg is perhaps exploitable as both a treatment goal and biomarker in future studies.
In conclusion, PPARg activation in these oral cancer cells includes (1) upregulation of two PPARg reporter genes, (2) nuclear PPARg protein upregulation upon western blot analysis, and 3) upregulation of nuclear PPARg/RXR a heterodimers on EMSA using the PPARg recognition sequence CYP4A1. The hypothesis of using PPARg treatments for oral cancer has been recently tested clinically in oral leukoplakia patients with the FDA approved thiazolidinedione pioglitazone (NCI contract N-01-15000; clinical trials.gov NCT 00099021).
